Unser Team der Klinik für Innere Medizin, Gastroenterologie und konservative Intensivmedizin

Geboren in Kiel

Hochschulausbildung

10/1982 - 10/1988
Studium der Medizin an der Christian Albrechts-Universität Kiel

11/1990
Approbation als Arzt

Klinischer Werdegang

02/1989 - 10/1989
Arzt im Praktikum in der Inneren Abteilung
Kreiskrankenhaus des Kreises Plön in Preetz

01/1990 - 10/1990
Arzt im Praktikum in der I. Medizinischen Klinik und Poliklinik
Johannes Gutenberg Universität Mainz

11/1990
Beginn der Tätigkeit als Assistenzarzt in der I. Med. Klinik und Poliklinik
Universität Mainz

11/1990

Facharzt für Innere Medizin

01/1998
Oberarzt in der I. Med. Klinik und Poliklinik
Universität Mainz

05/2000
Erwerb der Zusatzbezeichnung „Gastroenterologie“

11/2001
Oberarzt der Klinik für Gastroenterologie und Hepatologie
Universitätsklinikum Essen

06/2004
Ltd. Oberarzt der Klinik für Gastroenterologie und Hepatologie
Universitätsklinikum Essen

10/2011
Gründer und Koordinator des Lebertumorzentrums Essen

07/2013
Chefarzt der Medizinischen Klinik I
Evangelisches Klinikum Niederrhein, Duisburg

07/2020
Chefarzt der Medizinischen Klinik II - Gastroenterologie und Hepatologie
Sana Klinikum Duisburg

01/2021
Chefarzt der Klinik für Allgemeine Innere Medizin und Hepatologie
Kliniken Essen – Mitte

11/2022
Chefarzt der Klinik für Innere Medizin - Hepatologie, Gastroenterologie,
Infektiologie und Diabetologie
AMEOS Einrichtungen Oberhausen

1. F. Schlaak, E. Hermann, M. Ringhoffer, P. Probst, H. Gallati, K.-H. Meyer zum Büschenfelde, B. Fleischer (1992): Predominance of Th1-type T cells in synovial fluid of patients with Yersinia-induced reactive arthritis. Eur. J. Immunol. 22, 2771-2776. IF: 4,518
   
   
2. F. Schlaak, H. Löhr, H. Gallati, K.-H. Meyer zum Büschenfelde, B. Fleischer (1993): Analysis of the in vitro cytokine production by liver-infiltrating T cells of patients with autoimmune hepatitis. Clin. Exp. Immunol. 94, 168-173. IF: 3,278
   
   
3. F. Schlaak, E. Hermann, H. Gallati, K.-H. Meyer zum Büschenfelde, B. Fleischer (1994): Differential effects of IL-10 on proliferation and cytokine production of human g/d and a/b T cells. Scand. J. Immunol. 39, 209-215. IF: 1,882
   
   
4. F. Schlaak, E. Schmitt, C. Hüls, K.-H. Meyer zum Büschenfelde, B. Fleischer (1994): A sensitive and specific bioassay for the detection of human interleukin-10. J. Immunol. Methods. 168, 49-54. IF: 2,005
   
   
5. F. Schlaak, P. Nieder, K.-H. Meyer zum Büschenfelde, B. Fleischer (1994): Human T helper cells reactive with somatic bacterial antigens belong to the Th1 subset. Med. Microbiol. Immunol. 183, 169-175. IF: 2,433
   
   
6. F. Schlaak, M. Buslau, W. Jochum, E. Hermann, M. Girndt, H. Gallati, K.-H. Meyer zum Büschenfelde, B. Fleischer (1994): T cells involved in psoriasis vulgaris belong to the Th1 subset. J. Invest. Dermatol. 102[2], 145-149. IF: 6,372
   
   
7. F. Löhr, J. F. Schlaak, G. Gerken, B. Fleischer, H.-P. Dienes, K.-H. Meyer zum Büschenfelde (1994): Phenotypical analysis and cytokine release of liver-infiltrating and peripheral blood T lymphocytes from patients with chronic hepatitis of different etiology. Liver. 14, 161-166. IF: 4,412
8. Claus, J. F. Schlaak, M. Dittmayer, K.-H. Meyer zum Büschenfelde, W. Dippold. Inhibition of antibody-induced proliferation of human CD8⁺ T cells by CD16⁺ natural killer cells (1994): Eur. J. Immunol. 24, 1208-1212. IF: 4,518
   
   
9. F. Schlaak, A. Schwarting, P. Knolle, K.-H. Meyer zum Büschenfelde, W. Mayet (1995): Effects of Th1 and Th2 cytokines on cytokine production and ICAM-1 expressionon synovial fibroblasts. Ann. Rheum. Dis. 54[7], 560-565. IF: 8,727
   
   
10. F. Schlaak, C. Clauss, K.-H. Meyer zum Büschenfelde, W. Dippold (1995): Anti-GD3 antibodies are potent activators of human g/d and a/b positive T cells. Scand. J. Immunol. 41[5], 474-480. IF: 1,882
    
    
11. Knolle, J. F. Schlaak, A. Uhrig, P. Kempf, K.-H. Meyer zum Büschenfelde, G. Gerken (1995): Human Kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge. J. Hepatol. 22[2], 226-229. IF: 10,401
    
    
12. F. Löhr, J. F. Schlaak, H. P. Dienes, J. Lorenz, K.-H. Meyer zum Büschenfelde, G. Gerken (1995): Liver cirrhosis associated with heterozygous alpha-1-antitrypsin deficiency type Pi MS and autoimmune features. Digestion. 56[1], 41-45. IF: 2,032
    
    
13. Girndt, H. Köhler, E. Schiedhelm-Weick, J. F. Schlaak, K.-H. Meyer zum Büschenfelde, B. Fleischer (1995): Production of interleukin-6, tumor necrosis factor a and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int. 47[2], 559-565. IF: 8,520
    
    
14. F. Löhr, W. Weber, J. F. Schlaak, B. Goergen, K.-H. Meyer zum Büschenfelde, G. Gerken (1995): Proliferative response of CD4⁺ T cells and hepatitis B virus clearance in chronic hepatitis with or without hepatitis B e-minus hepatitis B virus mutants. Hepatology. 22[1], 61-68. IF: 11,190
    
    
15. F. Löhr, J. F. Schlaak, G. Kollmannsperger, H.-P. Dienes, K.-H. Meyer zum Büschenfelde, G. Gerken (1996): Liver-infiltrating and circulating CD4⁺ T cells in chronic hepatitis C: immunodominant epitopes, HLA-restriction and functional significance. Liver. 16, 174-182. IF: 4,412
    
    
16. F. Schlaak, I. Pfers, K.-H. Meyer zum Büschenfelde, E. Märker-Hermann (1996): Different cytokine profiles in the synovial fluid of patients with osteoarthritis, rheumatoid arthritis and seronegative spondylarthropathies. Clin. Exp. Rheumatol. 14, 155-162. IF: 2,973
    
    
17. Zissel, J. F. Schlaak, M. Schlaak, J. Müller-Quernheim (1996): Regulation of cytokine release by alveolar macrophages treated with interleukin-4, interleukin-10, or transforming growth factor beta. Eur. Cytokine Netw. 7[1], 59-66. IF : 1,800
    
    
18. Heike, J. F. Schlaak, H. Schulze-Bergkamen, S. Heyl, W. Herr, U. Schmitt, P. M. Schneider, K.-H. Meyer zum Büschenfelde (1996): Specificities and functions of CD4⁺ HLA class II-restricted T cell clones against a human sarcoma: evidence for several recognized antigens. J. Immunol. 156[6], 2205-2213. IF: 5,362
    
    
19. Schwarting, J. F. Schlaak, J. Lotz, I. Pfers, K.-H. Meyer zum Büschenfelde, W. Mayet (1996): Endothelin-1 modulates the expression of adhesion molecules on synovial fibroblast-like synovial cell (FLS). Scand. J. Rheumatol. 25, 246-256. IF: 2,607
    
    
20. Zissel, J. Homolka, J. F. Schlaak, M. Schlaak, J. Müller-Quernheim (1996): Anti-inflammatory cytokine release by alveolar macrophages in pulmonary sarcoidosis. Am. J. Resp. Crit. Care Med. 154, 713-719. IF: 11,986
    
    
21. F. Löhr, J. F. Schlaak, A. W. Lohse, W. O. Böcher, M. Arenz, G. Gerken, K.-H. Meyer zum Büschenfelde (1996): Autoreactive CD4⁺ LKM-specific and anticlonotypic T-cell responses in LKM-1 antibody-positive autoimmune hepatitis. Hepatology. 24, 1416-1421. IF: 11,190
    
    
22. Heike, J. F. Schlaak, S. Heyl, H. Schulze-Bergkamen, U. Schmitt, K.-H. Meyer zum Büschenfelde (1997): Contrary roles of IL-4 and IL-12 on IL-10 production and proliferation of human tumour reactive T cells. Scand. J. Immunol. 45[2], 221-226. IF: 1,882
    
    
23. Schwarting, J. F. Schlaak, E. Wandel, K.-H. Meyer zum Büschenfelde, W. Mayet (1997): Human renal tubular epithelial cells as target cells for antibodies to proteinase 3 (c-ANCA). Nephrol. Dial. Transplant. 12[5], 916-923. IF: 3,488
    
    
24. F. Schlaak, M. Trippler, I. Ernst, K.-H. Meyer zum Büschenfelde, G. Gerken (1997): Chronic hepatitis C: The viral load per liver cell before treatment as a new marker to predict long-term response to IFN-a therapy. J. Hepatol. 27[5], 917-921. IF: 10,401
    
    
25. Barbulescu, C. Becker, J. F. Schlaak, E. Schmitt, K.-H. Meyer zum Büschenfelde (1998): Cutting edge: IL-12 and IL-18 differentially regulate the transcriptional activity of the human IFN-g promoter in primary CD4⁺ T lymphocytes. J. Immunol. 160[8], 3642-3647. IF: 5,362
    
    
26. F. Schlaak, T. Pitz, H.F. Löhr, G. Gerken, K.-H. Meyer zum Büschenfelde (1998): IL-12 enhances deficient HCV-antigen induced Th1-type immune response of peripheral blood mononuclear cells. J. Med. Virol. 56, 112-117. IF: 2,217
    
    
27. F. Löhr, S. Krug, W. Herr, S. Weyer, J. F. Schlaak, T. Wölfel, G. Gerken, K.-H. Meyer zum Büschenfelde (1998): Quantitative and functional analysis of core-specific T-helper cell and CTL activities in acute and chronic hepatitis B. Liver. 18, 405-413. IF: 4,412
    
    
28. Hildner, E. Märker-Hermann, J. F. Schlaak, C. Becker, T. Germann, E. Schmitt, K.-H. Meyer zum Büschenfelde, M. F. Neurath (1998): Azathioprine, mycophenolate mofetil and methotrexate specifically modulate cytokine production by T cells. Ann. New York Acad. Sci. USA. 859, 204-207. IF: 3,155
    
    
29. F. Neurath, R. Wanitschke, M. Peters, K. Hildner, R. Tufan, K.-H. Meyer zum Büschenfelde, J. F. Schlaak (1998). Mycophenolate mofetil for treatment of active inflammatory bowel disease. Clinical and immunological studies. Ann. New York Acad. Sci. USA. 859, 315-318. IF: 3,155
    
    
30. F. Löhr, G. Gerken, M. Roth, S. Weyer, J. F. Schlaak, K.-H. Meyer zum Büschenfelde (1998): The cellular immune responses induced in the follow-up of interferon-alpha treated patients with chronic hepatitis C may determine the therapy outcome. J. Hepatol. 29[4], 524-532. IF: 10,401
    
    
31. O. Böcher, S. Herzog-Hauff, J. F. Schlaak, K.-H. Meyer zum Büschenfelde, H. F. Löhr (1999): Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: stimulation of the in vitro antibody response by interferon gamma. Hepatology. 29[1], 238-244. IF: 11,190
    
    
32. F. Neurath, K. Hildner, C. Becker, J. F. Schlaak, K. Barbulescu, T. Germann, E. Schmitt, P. Schirmacher, S. Haralambous, M. Pasparakis, G. Kollias, E. Märker-Hermann (1999): Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression. Clin. Exp. Immunol. 115[1], 42-55. IF: 3,278
    
    
33. F. Schlaak, G. Tully, H.F. Löhr, G. Gerken, K.-H. Meyer zum Büschenfelde (1999): HBV-specific immune defect in chronic hepatitis B is correlated with a dysregulation of pro- and antiinflammatory cytokines. Clin. Exp. Immunol. 115, 508-514. IF: 3,278
    
    
34. F. Neurath, R. Wanitschke, M. Peters, F. Krummenauer, K.-H. Meyer zum Büschenfelde, J. F. Schlaak (1999): Randomised trial of mycophenolate mofetil for treatment of chronic active Crohn´s disease. Gut. 44[5], 625-628. IF: 13,319
    
    
35. F. Schlaak, G. Tully, H. F. Löhr, G. Gerken, K.-H. Meyer zum Büschenfelde (1999): The presence of high amounts of HBV-DNA in serum is associated with suppressed costimulatory effects of interleukin 12 on HBV-induced immune response. J. Hepatol. 30, 353-358. IF: 10,401
    
    
36. Hildner, S. Finotto, C. Becker, J. F. Schlaak, P. Schirmacher, P. R. Galle, E. Märker-Hermann, M. F. Neurath (1999): Tumour necrosis factor (TNF) production by T cell receptor-primed T lymphocytes is a target for low dose methotrexate in rheumatoid arthritis. Clin. Exp. Immunol. 118, 137-146. IF: 3,278
    
    
37. J. Mayet, A. Schwarting, A. P. Barreiros, J. F. Schlaak, M. F. Neurath (1999): Anti-PR-3 antibodies induce endothelial IL-8 release. Eur. J. Clin. Invest. 29, 973-979. IF: 2,834
    
    
38. J. Mayet, E. Märker-Hermann, J. F. Schlaak, K.-H.Meyer zum Büschenfelde (1999): Irregular cytokine pattern of CD4+ T lymphocytes in response to Staphylococcus aureus in patients with Wegener's granulomatosis. Scand. J. Immunol. 49[6], 585-594. IF: 1,882
    
    
39. P. Barreiros, P. Schirmacher, R. Laufenberg-Feldmann, K.-H. Meyer zum Büschenfelde, J. F. Schlaak (2000): The early immune response in the liver of BALB/c mice infected with S. typhimurium. Scand. J. Immunol. 51[5], 472-478. IF: 1,882
    
    
40. Orth, M. Peters, J. F. Schlaak, F. Krummenauer, R. Wanitschke, W. J. Mayet, P. R. Galle, M. F. Neurath (2000): Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Am. J. Gastroenterol. 98[5]: 1201-1207. IF: 9,213
    
    
41. Atreya, J. Mudter, S. Finotto, J. Mullberg, T. Jostock, S. Wirtz, M. Schutz, B. Bartsch, M. Holtmann, C. Becker, D. Strand, J. Czaja, J. F. Schlaak, H. A. Lehr, F. Autschbach, G. Schurmann, N. Nishimoto, K. Yoshizaki, H. Ito, T. Kishimoto, P. R. Galle, S. Rose-John, M. F. Neurath (2000): Blockade of interleukin 6 transsignaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat. Med. 6[5], 583-588. IF: 28,054
    
    
42. Micke, K. M. Beeh, J. F. Schlaak, R.Buhl (2001). Oral supplementation with whey proteins increases plasma glutathione levels of HIV-infected patients. Eur. J. Clin. Invest 31[2], 171-178. IF: 2,834
    
    
43. Strobl, V. Arulampalam, H. Is'harc, S. J. Newman, J. F. Schlaak, D. Watling, A.P.Costa-Pereira, F. Schaper, I. Behrmann, K. C. Sheehan, R. D. Schreiber, F. Horn, P. C. Heinrich, I. M. Kerr (2001). A completely foreign receptor can mediate an interferon-gamma-like response. EMBO J. 20[19], 5431-5442. IF: 10,748
    
    
44. F. Schlaak, A.P. Barreiros, S. Pettersson, P. Schirmacher, K.H. Meyer zum Büschenfelde, M.F. Neurath (2001). Antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappaB abrogate fulminant septic shock induced by S. typhimurium in mice. Scand. J. Immunol. 54[4], 396-403. IF: 1,882
    
    
45. Aberger, A. P. Costa-Pereira, J. F. Schlaak, T. M. Williams, R. F. O'Shaughnessy, G. Hollaus, I. M. Kerr, A. M. Frischauf (2001). Analysis of Gene Expression Using High-Density and IFN-gamma-Specific Low-Density cDNA Arrays. Genomics 77[1/2], 50-57. IF: 2,793
    
    
46. F. Schlaak, C. Schramm, K. Radecke, K.-H. Meyer zum Büschenfelde, G. Gerken. Sustained suppression of HCV replication and inflammatory activity after interleukin-2 therapy in patients with HIV/Hepatitis C coinfection (2002). J. Acquir. Immune. Defic. Syndr. 29[2], 145-148. IF: 4,425
    
    
47. P. Costa-Pereira, S. Tininini, B. Strobl, T. Alonzi, J. F. Schlaak, H. Is'harc, I. Gesualdo, S. J. Newman, I. M. Kerr, V. Poli. Mutational switch of an IL-6 response to an interferon-gamma -like response (2002). P. Natl. Acad. Sci. USA 99[12], 8043-8047. IF: 9,809
    
    
48. F. Schlaak, C.M.U. Hilkens, A.P. Costa-Pereira, B. Strobl, F. Aberger, A.M. Frischauf, I.M. Kerr (2002). Cell-type and donor-specific transcriptional responses to interferon-alpha – use of customised gene arrays. J. Biol. Chem. 277[51], 49428-37. IF: 4,600
    
    
49. P. Barreiros, J.F. Schlaak, G. Gerken, P.R. Galle, H.F. Löhr. Interleukin-2 has no additional therapeutic efficacy in the retreatment of patients with chronic hepatitis C that had not responded to interferon-alpha plus ribavirin (2003). Eur. J. Clin. Invest. 33(7):628-9. IF: 2,834
    
    
50. Strahle, D. Garcin, P. Le Mercier, J.F. Schlaak, D. Kolakofsky. Sendai virus targets inflammatory responses, as well as the interferon-induced antiviral state, in a multifaceted manner (2003). J. Virol. 77(14):7903-13. IF: 4,648
    
    
51. M.U. Hilkens, J.F. Schlaak, I.M. Kerr. Differential Responses to IFN-alpha Subtypes in Human T Cells and Dendritic Cells (2003). J. Immunol. 171(10):5255-63. IF: 5,362
    
    
52. Luik, S. Knapp, M. Thursz, H.C. Thomas, J.F. Schlaak. Autoregulatory role of Interleukin-10 in hepatitis C patients treated with IFN-α (2004). J. Interf. Cytok. Res. 24(10): 585-593. IF: 3,899
    
    
53. Jones, A. Davidson, L. Hibbert, P. Grünewald, J.F. Schlaak, S. Ball, G.R. Foster, M. Jacobs. Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression (2005). J. Virol. 79(9):5414-20. IF: 4,648
    
    
54. Zoepf, E.J. Maldonado-Lopez, P. Hilgard, A. Dechene, M. Malago, C.E. Broelsch, J. F. Schlaak, G. Gerken. Diagnosis of biliary strictures after liver transplantation: Which is the best tool? (2005). World J. Gastroenterol. 11(19):2945-8. IF: 2,433
    
    
55. Guan, H. Liu, D. Yang, M. Lu, M. Roggendorf, J. F. Schlaak. Establishment of a new low-density cDNA macroarray and the application in the activity of IFN against HBV (2005). Chin J Exp Clin Virol. 19(3):236-9.
    
    
56. Zoepf, E. Maldonado-Lopez, P. Hilgard, J. F. Schlaak, M. Malago, C.E. Broelsch, U. Treichel, G. Gerken. Endoscopic therapy of posttransplant biliary stenoses after right-sided adult living donor liver transplantation (2005). Clin. Gastroenterol. Hepatol. 3(11):1144-9. IF: 6,543
    
    
57. Erim, M. Beckmann, C. Valentin-Gamazo, M. Malago, A. Frilling, J. F. Schlaak, G. Gerken, C. E. Broelsch, W. Senf. Quality of Life and Psychiatric Complications after Adult Living Donor Liver Transplantation (2006). Liver Transpl., 12(12):1782-90. IF: 3,793
    
    
58. Guan, M. Lu, P. Grünewald, M. Roggendorf, G. Gerken, J. F. Schlaak. The interferon-alpha response in HBV-transfected HepG2.2.15 cells is partially restored by lamivudine treatment (2007). World J. Gastroenterol., 13(2): 234-241. IF: 2,433
    
    
59. Bockhorn, A. Frilling, T. Benkö, J. Best, S.-Y. Sheu, M. Trippler, J. F. Schlaak, Broelsch CE. Tri-iodothyronine as a stimulator of liver regeneration after partial and subtotal hepatectomy (2007). Eur. Surg. Res., 39(1):58-63. IF: 1,431
    
    
60. Bockhorn, S. Schöllmann, B. Opitz, G.C. Sotiropoulos, S.-Y. Sheu, E. Niehues, M. Trippler, A. Frilling, C.E. Broelsch, J. F. Schlaak. VEGF does not improve liver regeneration and survival after 90% subtotal liver resection (2007), Hepatol. Res., 37(5):353-9. IF: 2,218
    
    
61. Bockhorn, M. Goralski, D. Prokofiev, P. Dammann, P. Grünewald, M. Trippler, M. Kamler, A. Frilling, C. E. Broelsch, J. F. Schlaak. VEGF is important for early liver regeneration after partial hepatectomy (2007). J. Surg. Res., 138(2):291-9. IF: 2,121
    
    
62. Wu, M. Lu, Z. Meng, M. Trippler, M. Roggendorf, G. Gerken, J. F. Schlaak. TLR-mediated control of HBV replication by non-parenchymal liver cells in mice (2007). Hepatology, 46(6):1769-1778. IF: 11,190
    
    
63. Bockhorn, T. Benkö, B. Opitz, S.-Y. Sheu, G. C. Sotiropoulos, J. F. Schlaak, C. E. Broelsch, H. Lang. Impact of hepatic vein deprivation on liver regeneration and function after major hepatectomy (2008). Langenbeck Arch. Surg., 393(4):527-33. IF: 2,160
    
    
64. Erim, M. Beckmann, C. Valentin-Gamazo, M. Malago, A. Frilling, J. F. Schlaak, G. Gerken, C. E. Broelsch, W. Senf. Selection of donors for adult living-donor liver donation: results of the assessment of the first 205 donor candidates (2008). Psychosomatics, 49(2):143-51. IF: 1,669
    
    
65. Broering, J. Wu, Z. Meng, P. Hilgard, M. Lu, M. Trippler, A. Szczeponek, G. Gerken, J. F. Schlaak. TLR stimulated non-parenchymal liver cells are potent suppressors of HCV replication (2008). J. Hepatol., 48(6):914-22. IF: 10,401
    
    
66. Bockhorn, C. D. Fingas, Y. Gu, U. Rauen, E. Niehues, A. Frilling, C. E. Broelsch, J. F. Schlaak. Erythropoietin improves liver regeneration and survival in rat models of extended liver resection and living donor liver transplantation (2008). Transplantation, 86(11):1578-85. IF: 3,535
    
    
67. -P. Sowa, J. Best, T. Benko, M. Bockhorn, Y. Gu, A. Bucchi, G. Gerken, U. Rauen, J. F. Schlaak. The extent of liver resection modulates the activation of transcription factors and the production cytokines that are involved in liver regeneration (2008). World. J. Gastroenterol., 14(46):7093-100. IF: 2,433
    
    
68. Meng, S. Qiu, X. Zhang, J. Wu, T. Schreiter, Y. Xu, D. Yang, M. Roggendorf, J. F. Schlaak, M. Lu. Inhibition of woodchuck hepatitis virus gene expression in primary hepatocytes by siRNA enhances the cellular gene expression (2009). Virology, 384(1):88-96. IF: 3,278
    
    
69. Wu, Z. Meng, J. Min, R. Pei, M. Trippler, R. Broering, A. Bucchi, J.-P. Sowa, U. Dittmer, D. Yang, M. Roggendorf, G. Gerken, M. Lu, J. F. Schlaak. HBV suppresses Toll-like receptor mediated innate immune responses in murine parenchymal and non-parenchymal liver cells (2009). Hepatology, 49(4):1132-40. IF: 11,190
    
    
70. Wang, M. Trippler, M. Lu, R. Broering, G. Gerken, J. F. Schlaak. Toll-like receptor activated human and murine hepatic stellate cells are potent regulators of hepatitis C virus replication (2009). J. Hepatol. 2009;51(6):1037-45. IF: 10,401
    
    
71. Zhang, Z. Meng, S. Qiu, Y. Xu, D. Yang, J. F. Schlaak, M. Roggendorf, M. Lu. Lipopolysaccharide induced innate immune responses in primary hepatocytes inhibit woodchuck hepatitis virus replication via interferon-independent pathways (2009). Cell. Microbiol. 11(11):1624-37. IF: 4,816
    
    
72. R. Rani, Y. Xu, J. C. Lee, J. Shrock, A. Josyula, J. F. Schlaak, S. Chakraborthy, N. Ja, R.M. Ransohoff, R. A. Rudick. Heterogeneous, longitudinally stable molecular signatures in response to interferon-beta (2009). Ann. N. Y. Acad. Sci. 1182:58-68. IF: 3,155
    
    
73. Wu, Z. Meng, M. Jiang, E. Zhang, M. Trippler, R. Broering, A. Bucchi, F. Krux, U. Dittmer, D. Yang, M. Roggendorf, G. Gerken, M. Lu, J. F. Schlaak. TLR induced innate immune response in non-parenchymal liver cells are cell type-specific (2010). Immunology. 129 (3), 363-374. IF: 3,735
    
    
74. Erim, S. Tagay, M. Beckmann, S. Bein, V. Cicinatti, S. Beckebaum, W. Senf, J. F. Schlaak. Depression and Protective Factors of Mental Health in People with Hepatitis C: a questionnaire survey (2010). Int. J. Nurs. Stud. 47(3):342-349. IF: 2,248
    
    
75. Benkö, S. Frede, Y. Gu, J. Best, H.A. Baba, J. F. Schlaak, H. de Groot, J. Fandrey, U. Rauen. Glycine pretreatment ameliorates liver injury after partial hepatectomy in the rat (2010). J. Invest. Surg., 23(1):12-20. IF: 1,191
    
    
76. Broering, M. Trippler, M. Jiang, M. Lu, G. Gerken, J. F. Schlaak. The interferon stimulated gene 15 functions as a proviral factor for the hepatitis C virus and as an attenuator of the IFN response in hepatocytes (2010). Gut, 59(8):1111-9. IF: 13,319
    
    
77. Burbelo, J. Kovacs, K. Ching, A. Issa, M. Iadarola, J. F. Schlaak, H. Masur, M. Polis, S. Kottilil. Proteome-wide anti-HCV and anti-HIV antibody profiling for predicting and monitoring response to HCV treatment in HIV co-infected patients (2010). J. Infect. Dis., 15;202(6):894-8. IF: 5,778
    
    
78. Ertle, A. Dechêne, J.-P. Sowa, V. Penndorf, K. Herzer, G. Kaiser, J. F. Schlaak, G. Gerken, W.-K. Syn, A. Canbay. Nonalcoholic fatty liver disease progresses to HCC in the absence of apparent cirrhosis (2011). Int. J. Cancer. 1;128(10):2436-43. IF: 5,007
    
    
79. Zhang, Z. Ma, E. Zhang, M. Jiang, J. F. Schlaak, M. Roggendorf, M. Lu. Modulation of HBV replication and hepatocyte differentiation by MicroRNA-1 (2011). Hepatology, 53(5):1476-85. IF: 11,190
    
    
80. Katsounas, M. Trippler, S. Bein, S. Kottilil, R. A. Lempicki, G. Gerken, J. F. Schlaak. Altered Expression of SHIP, a Toll-like Receptor 2 and 4 Pathway Inhibitor, is Associated with the Severity of Liver Fibrosis in Chronic Hepatitis C Virus Infection (2011). J. Infect. Dis., 204(8):1181-5. IF: 5,778
    
    
81. Montag, R. Broering, J. Min, M. Lu, J.-P. Sowa, G. Gerken, J. F. Schlaak. Corticosteroids shift the response pattern of the hepatic innate immune system from an inflammatory to an anti-inflammatory state (2011). Int. Immunol., 23(9):537-44. IF: 3,181
    
    
82. C. Lauenstein, T.A. Heusner, M. Hamami, J. Ertle, J. F. Schlaak, G. Gerken, A. Bockisch, G. Antoch. Radioembolization of hepatic tumors: flow redistribution after the occlusion of intrahepatic arteries (2011). Rofo, 183(11):1058-1064. IF: 1,961
    
    
83. Wu, M.F. Chen, Y.C. Xia, Y. Guo, Y. Lin, C. Sun, C.Y. Zhang, Y. Chen, S.P. Liu, Y.H. Hao, M. Lu, J.F. Schlaak., D.L. Yang. Toll-like receptor dependent innate immune responses by primary mouse hepatocytes and its control of HBV replication (2011). Chin. J. of Hepatol., 19(11):838-42.
    
    
84. Katsounas, M. Trippler, B. Wang, M. Polis, R. A. Lempicki, S. Kottilil, G. Gerken, J. F. Schlaak. CCL5 is a marker for early fibrosis in chronic hepatitis C and is regulated by Toll-like receptor 3 signaling and interferon-α therapy (2012). J. Viral Hep., 19(2):128-37. IF: 3,307
    
    
85. Naggie, A. Osinusi, A. Katsounas, E. Hermann, R. Lempicki, J.F. Schlaak, A. Thompson, P. Clark, M. Trippler, K. Patel, B. Shivakumar, A. Muir, J. McHutchison, D. Goldstein,  H. Masur, M. A. Polis, S. Kottilil. Dysregulation Of Host Innate Immunity In HIV/HCV Genotype 1 Infected IL28B CT/TT Haplotype Patients Associated With Depressed Viral Kinetics And Therapeutic Response (2012). Hepatology. 56(2):444-54. IF: 11,190
    
    
86. Osinusi, S. Naggie, S. Poonia, M. Trippler, Z. Hu, J. F. Schlaak, D. Fishbein, H. Masur, M. Polis, S. Kottilil. ITPA Gene Polymorphisms Significantly Affect Hemoglobin Decline and Treatment Outcomes in HIV/HCV Co-infected Patients (2012). J. Med. Virol., 84(7):1106-14. IF: 2,217
    
    
87. Katsounas, M. Trippler, S. Kottilil, R. A. Lempicki, C. H. Lane, G. Gerken, J. F. Schlaak. Cytokine/Chemokine patterns connect various host and viral characteristics with clinics during chronic hepatitis C (2012). Eur. J. Med. Res., 11;17(1):9. IF: 1,398
    
    
88. Theysohn, J. F. Schlaak, S. Müller, J. Ertle, T. W. Schlosser, A. Bockisch, T. C. Lauenstein. Selective internal radiation therapy of hepatocellular carcinoma: potential hepatopulmonary shunt reduction after Sorafenib administration (2012). J. Vasc. Int. Radiol., 23(7):949-52. IF: 2,149
    
    
89. Zhang, Z. Ma, H. Liu, J. Liu, Z. Meng, R. Broering, D. Yang, J. F. Schlaak, M. Roggendorf, M. Lu. Role of Toll-like receptor 2 in the immune response against Hepadnaviral infection (2012). J. Hepatol., 57(3):522-8. IF: 10,401
    
    
90. F. Schlaak, M. Trippler, Y. Erim, B. Kis, B. Wang, N. Scherbaum, G. Gerken. Common pathways in endogenous depression and depression induced by IFN-α therapy for chronic hepatitis C (2012). PLoS One, 7(6):e38668. IF: 3,534
    
    
91. Ren, S. Esser, C. Jochum, J. F. Schlaak, G. Gerken, D. Schadendorf, U. Dittmer, G. Wu, Z. Yuan, J. Timm. IL-21 augments the HBV-specific CD8+T cell response in vitro in patients coinfected with HIV-1 (2012). AIDS, 26(17):2145-53. IF: 6,557
    
    
92. M. Theysohn, S. Müller, J. F. Schlaak, J. Ertle, T. W. Schlosser, A. Bockisch, T. C. Lauenstein. Selective Internal Radiation Therapy (SIRT) of hepatic tumors: how to deal with the cystic artery (2012). Cardiovasc Intervent Radiol., 36(4):1015-22. IF: 1,965
    
    
93. M. Ertle, D. Heider, M. Wichert, B. Keller, R. Kueper, P. Hilgard, G. Gerken, J. F. Schlaak. Combination of Alphafetoprotein and Des-Gamma-Carboxy Prothrombin is superior in detection of Hepatocellular Carcinoma (2013). Digestion, 87:121-131. IF: 2,032
    
    
94. Katsounas, J. J. Hubbard, C. H. Wang, X. Zhang, D. Dou, B. Shivakumar, S. Winter, J. F. Schlaak, R. A. Lempicki, H. Masur, M. Polis, S. Kottilil, A. Osinusi. High Interferon Stimulated Gene ISG-15 Expression Affects HCV Treatment Outcome in HIV/HCV Coinfected Patients (2013). J. Med. Virol., 85(6):959-63. IF: 2,217
    
    
95. Schuchmann, J.M. Kittner, J. F. Schlaak, D. Klass, N. Dikopolous, C. Eisenbach, T. Berg, C. Trautwein, R. Günther, S. Zeuzem, R. Gösseringer, A. Ehrlich, K. Neumann, D. Wachtlin, M.F. Sprinzl, T. Zimmermann, W.O. Böcher, P.R. Galle. Viral efficacy and safety of all-trans retinoic acid in HCV patients with previous non-response (2013). Digest. Liver. Dis., 45(4):323-9. IF: 2,889
    
    
96. A. Tucci, R. Bröring, P. Johansson, J. F. Schlaak, R. Küppers. B cells in chronically hepatitis C virus-infected individuals lack a virus-induced mutation signature in the TP53, CTNNB1, and BCL6 genes (2013). J. Virol., 87(5):2956-62. IF: 4,648
    
    
97. A. Megger, T. Bracht, M. Kohl, M. Ahrens, F. Weber, A.-C. Hoffmann, C. Stephan, M. Eisenacher, J. F. Schlaak, H. A. Baba, H. E. Meyer, B. Sitek. Combining different quantification techniques in proteomics-based clinical studies reveals confident hepatocellular carcinoma biomarker candidates (2013). Mol. Cell. Proteomics, 12(7):2006-20. IF: 7,254
    
    
98. Kohl M, Megger DA, Trippler M, Meckel H, Ahrens M, Bracht T, Weber F, Hoffmann AC, Baba HA, Sitek B, Schlaak JF, Meyer HE, Stephan C, Eisenacher M. A practical data processing workflow for multi - OMICS projects (2013). Biochim Biophys Acta. doi:pii: S1570-9639(13)00092-7. IF: 3,191
    
    
99. Nel, H. A. Baba, J. Ertle, F. Weber, B. Sitek, M. Eisenacher, H. E. Meyer, J. F. Schlaak, A.-C. Hoffmann. Individual profiling of circulating tumor cell composition and therapeutic outcome in patients with hepatocellular carcinoma (2013). Translat. Oncol., 6(4):420-8. IF: 2,558
    
    
100. Pei, B. Qin, X. Zhang, W. Zhu, T. Kemper, Z. Ma, M. Trippler, J. F. Schlaak, X. Chen, M. Lu. Interferon-induced protein with tetratricopeptide repeats 1 and 2 are cellular factors that limit hepatitis B virus replication (2013). J. Innate Immun., 6(2):182-91. IF: 4,557
     
     
101. Broering, C. I. Real, K. Jahn-Hofmann, L. Ickenstein, M. John, M. Lutterbeck, K. Kleinehr, G. Gerken, J. F. Schlaak. Chemical modifications on siRNAs avoid the Toll-like receptor-mediated activation of the hepatic immune system in vivo and in vitro (2013). Int. Immunol., 26(1):35-46. IF: 3,181
     
     
102. Broering, M. Lutterbeck, K. Kleinehr, M. Trippler, L. Poggenpohl, A. Paul, G. Gerken, J. F. Schlaak. Longterm stimulation of toll-like receptor 3 in primary human hepatocytes leads to sensitization for antiviral responses induced by poly I:C treatment (2014). J. Viral Hep., 21(7):480-90. IF: 3,307
     
     
103. Jiang, R. Broering, M. Trippler, L. Poggenpohl, G. Gerken, M. Lu, J. F. Schlaak. Toll-like receptor-mediated im mune responses are attenuated in the presence of the hepatitis B virus surface antigen (2014). J. Viral Hep., 21(12):860-72. IF: 3,307
     
     
104. Weng, J. Ertle, S. Zheng, T. Lauenstein, S. Mueller, A. Bockisch, G. Gerken, D. Yang, J. F. Schlaak. Choi criteria are superior in evaluating tumor response in patients treated with transarterial radioembolization for hepatocellular carcinoma (2013). Oncol. Lett., 6: 1707-1712, 2013. IF: 0,987
     
     
105. Real, D. Megger, B. Sitek, K. Jahn-Hofmann, L. Ickenstein, M. John, K. Kuhlmann, M. Eisenacher, H. E. Meyer, G. Gerken, R. Broering, J. F. Schlaak. Identification of Proteins that Mediate the Pro-viral Functions of the Interferon Sensitive Gene 15 in Hepatitis C Virus Replication (2013). Antivir. Res., 100(3):654-61. IF: 3,434
     
     
106. Gu, J.-P. Sowa, S. Zhang, A. Paul, G. Gerken, J. F. Schlaak. VEGF improves liver regeneration and survival after 90% hepatectomy in a rat model of diet-induced steatosis (2013). Digestion, 22;88(4):235-242. IF: 2,032
     
     
107. Weng, J. Ertle, S. Zheng, T. Lauenstein, S. Mueller, A. Bockisch, G. Gerken, D. Yang, J. F. Schlaak. A new model to estimate prognosis after Yttrium-90 radioembolization in patients with hepatocellular carcinoma (2013). PLoS One, 8(12):e82225. IF: 3,534
     
     
108. Hoyo-Becerra, A. Huebener, M. Trippler, M. Lutterbeck, Z. Liu, K. Truebner, T. Bajanowski, G. Gerken, D.M. Hermann, J. F. Schlaak. Concomitant interferon alpha stimulation and TLR3 activation induces neuronal expression of depression-related genes that are elevated in the brain of suicidal persons (2013). PLoS One, 8(12):e83149. IF: 3,534
     
     
109. Hilgard, A. Dechene, A. Canbay, K. Herzer, J. F. Schlaak, U. Treichel, A. Gassel, H. Baba, T. Zoepf. Diagnostic Mini-Laparoscopy in hepatic diseases and primary liver- and bile duct cancer: An over 10-year experience in 1788 cases (2014). Digestion, 89(2):156-164. IF: 2,032
     
     
110. Liu, M. Jiang, Z. Ma, K. Dietze, G. Zelinskyy, D. Yang, U. Dittmer, J. F. Schlaak, M. Roggendorf, M. Lu. Stimulation of Mouse Liver Endothelial Cells by Toll-Like Receptor 1/2 Ligands shifts T cell suppression to anti-viral T cell immunity (2013). J. Immunol., 191(12):6178-90. IF: 5,362
     
     
111. Theysohn, J. Ertle, S. Müller, J. F. Schlaak, F. Nensa, S. Sipillae, A. Bockisch, T. C. Lauenstein. Hepatic volume changes after lobar Selective Internal Radiation Therapy (SIRT) of hepatocellular carcinoma (2013). Clin. Radiol. doi:pii: S0009-9260(13)00457-1. 10.1016/j.crad.2013.09.009. IF: 1,663
     
     
112. Jiang, R. Broering, M. Trippler, J. Wu, E. Zhang, X. Zhang, G. Gerken, M. Lu, J. F. Schlaak. MicroRNA-155 controls toll-like receptor 3- and hepatitis C virus-induced immune responses in the liver (2014). J. Viral Hep., 21(2):99-110. IF: 3,307
     
     
113. Schelhorn, J. Theysohn, J. Ertle, J. F. Schlaak, S. Müller, A. Bockisch, T. Lauenstein. Selective Internal Radiation Therapy of Hepatic Tumors: is coiling of the gastroduodenal artery always beneficial (2014)? Clin. Radiol., 69(5):e216-22. IF: 1,663
     
     
114. Baraniskin, S. Nöpel-Dünnebacke, C. Gerges, T. Bracht, B. Sitek, H. E. Meyer, J. F. Schlaak, J. Ertle, R. Schroers, C. Pox, W. Schmiegel, S. A. Hahn. Analysis of U2 small nuclear RNA fragments in the bile differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders (2014). Dig. Dis. Sci., 59(7):1436-41. IF: 2,550
     
     
115. A. Tucci, R. Broering, M. Lutterbeck, J. F. Schlaak, R. Küppers. Intrahepatic B cell follicles of chronically hepatitis C virus-infected individuals lack signs of an ectopic germinal center reaction (2014). Eur. J. Immunol., 44(6):1842-50. IF: 4,518
     
     
116. Katsounas, J. J. Rasimas, M. A. Polis, G. Guido, J. F Schlaak, R. A Lempicki, D. L. Rosenstein, S. Kottilil. Interferon Stimulated Gene ISG20 links psychiatric events to distinct Hepatitis C Virus responses in HIV patients (2014). J. Med. Virol., 86(8):1323-31. IF: 2,217
     
     
117. Thöns, C. Berger, M. Trippler, H. Siemann, M. Lutterbeck, R. Bröring, J. F. Schlaak, F. M. Heinemann, P.A. Horn, J. Nattermann, N. Scherbaum, G. Alter, J. Timm. KIR2DL3+NKG2A- Natural Killer Cells are Associated with Protection from Productive Hepatitis C Virus Infection in People who Inject Drugs (2014). J. Hepatol., 61(3):475-81. IF: 10,401.
     
     
118. Wu, M. Chen, Y. Lin, Y. Xia, C. Sun, J. Wang, Y. Guo, J. Song, E. Zhang, B. Wang, X. Zhen, J. F. Schlaak, M. Lu, D. Yang. Polyinosinic-polycytidylic acid treatment leads to the Interferon-dependent clearance of hepatitis B virus in a hydrodynamic injection mouse model (2014). J. Virol., 88(18):10421-31. IF: 4,648
     
     
119. El Fouly, J. Ertle, A. El Dorry, M. Shaker, H. Abdella, S. Mueller, E. Barakat, T. Lauenstein, A. Bockisch, G. Gerken, F. Schlaak. Intermediate Stage Hepatocellular Carcinoma: Radioembolization with Yttrium 90 or Chemoembolization (2014)? Liver Int., 35(2):627-35. 4,412.
     
     
120. Padden, D. A. Megger, T. Bracht, H. Reis, M. Kohl, M. Eisenacher, J. F. Schlaak, A. E. Canbay, F. Weber, A.-C. Hoffmann, K. Kuhlmann, H. E. Meyer, H. A. Baba, B. Sitek. Identification of novel biomarker candidates for the immunohistochemical diagnosis of cholangiocellular carcinoma (2014). Mol. Cell. Proteomics, 13(10):2661-72. IF: 7,254
     
     
121. Hoyo-Becerra, Z. Liu, J. Yao, B. Kaltwasser, D. M. Hermann, J. F. Schlaak. Rapid regulation of depression-associated genes in a new mouse model mimicking interferon-α-related depression in hepatitis C virus infection (2015). Mol. Neurobiol., 52(1):318-29. IF: 5,286
     
     
122. Nel, H.A. Baba, F. Weber, B. Sitek, M. Eisenacher, H.E. Meyer, J.F. Schlaak, A.C. Hoffmann. IGFBP1 in epithelial circulating tumor cells as a potential response marker to selective internal radiation therapy in hepatocellular carcinoma (2014). Biomark Med. 8(5):687-98. IF: 2,858
     
     
123. Schelhorn, T. Schlosser, J. Ertle, J. F. Schlaak, S. Müller, A. Bockisch, T. Lauenstein. Selective Internal Radiation Therapy of Hepatic Tumors: Procedural implications of a patent hepatic falciform artery (2014). Springerplus. 3:595.
     
     
124. Reis, C. Pütter, D. A. Megger, T. Bracht, F. Weber, A.-C. Hoffmann, J. Wohlschlaeger, S. Hagemann, M. Eisenacher, A. Scherag, J. F. Schlaak, A. Canbay, H. E. Meyer, B. Sitek, H. A. Baba. A structured proteomic approach identifies 14-3-3Sigma as a novel and reliable diagnostic protein biomarker in liver tumours (2015). BBA – Prot. Proteom., 1854(6):641-50. IF: 3,191
     
     
125. Zhang, J. Xia, B. Sun, Y. Dai, X. Li, J. F. Schlaak, M. Lu. In vitro and in vivo replication of a chemically synthesized consensus genome of hepatitis B virus genotype B (2015). J Virol Methods. pii: 213:57-64. IF: 1,883
     
     
126. Bracht, V. Schweinsberg, M. Trippler, M. Kohl, M. Ahrens, J. Padden, W. Naboulsi, D. A. Megger, M. Eisenacher, C. H. Borchers, J. F. Schlaak, C.-A. Hoffmann, F. Weber, H. A. Baba, H. E. Meyer, B. Sitek. Quantitative proteomics reveal the expression of fibulin-5 in association with hepatic fibrosis (2015). J. Proteome Res., 14(5):2278-86.
     
     
127. Reis, J. Padden, M. Ahrens, C. Pütter, S. Bertram, L. Pott, A.-C. Reis, F. Weber, B. Juntermanns, A.-C. Hoffmann, M. Eisenacher, J. F. Schlaak, A. Canbay, H. E. Meyer, B. Sitek, H. A. Baba. Differential proteomic and tissue expression analyses identify valuable diagnostic biomarkers of hepatocellular differentiation and hepatoid carcinomas (2015). Pathology, 47(6):543-50.
     
     
128. Werner, K. Kleinehr, S. Driftmann, K. Skibbe, J. Timm, Z. Mathé, J. Treckmann, G. Kaiser, A. Paul, G. Gerken, J. F. Schlaak, R. Broering. All-In-One: advanced human parenchymal and non-parenchymal liver cell preparation (2015). PLoS One, 10(9):e0138655.
     
     
129. Grüner, S. Viazov, K. Korn, A. Knöll, M. Trippler, J.F. Schlaak, G. Gerken, M. Roggendorf, R.S. Ross. Performance characteristics of the VERSANT hepatitis C virus RNA 1.0 (kPCR) assay (2015). Int J Med Microbiol. pii: S1438-4221(15)00075-2.
     
     
130. Noordeen, C. A. Scougall, A. Grosse, Q. Qiao, B. Baradaran, G. Reaiche-Miller, J. Finnie, M. Werner, R. Broering, J. F. Schlaak, A. Vaillant, A. R. Jilbert. Therapeutic antiviral effect of the nucleic acid polymer REP 1 2055 against persistent duck hepatitis B virus infection (2015). PLoS One, 10(11):e0140909.
     
     
131. Petersen, R. Heyne, S. Mauss, J. F. Schlaak, W. Schiffelholz, C. Eisenbach, H. Hartmann, M. Wiese, K. Boeker, H.-F. Loehr, C. John, M. Leuschner, C. Trautwein, G. Felten, A. Trein, W. Krause, S. Ruppert, T. Warger, D. Hueppe. Efficacy and safety of tenofovir disoproxil fumarate treatment in chronic hepatitis B patients: a 3 year prospective field practice study in Germany (2016). Dig Dis Sci, 61(10):3061-3071.
     
     
132. Naboulsi, D. A. Megger, T. Bracht, M. Kohl, M. Turewicz, M. Eisenacher, D. M. Voss, J. F. Schlaak, A.-C. Hoffmann, F. Weber, H. A. Baba, H. E. Meyer, B Sitek. Quantitative proteome analysis of hepatocellular carcinoma tissue reveals Versican as potential biomarker for early-stage HCC diagnosis (2016). J. Prot. Res., 15(1):38-47.
     
     
133. Broering, M. Trippler, M. Lutterbeck, C.I. Real, D.A. Megger, T. Bracht, B. Sitek, K. Kuhlmann, M. Eisenacher, H.E. Meyer, H.A. Baba, F. Weber, A.C. Hoffmann, G. Gerken, J. F. Schlaak. Hepatic expression of proteasome subunit alpha type-6 is upregulated during viral hepatitis and putatively regulates the expression of ISG15 ubiquitin-like modifier, a proviral host gene in hepatitis C virus infection (2016). J. Viral Hep., 23(5):375-86.
     
     
134. Berhane, H. Toyoda, T. Tada, T. Kumada, C. Kagebayashi, S. Satomura, N. Schweitzer, A. Vogel, M. P. Manns, J. Benckert, T. Berg, J. Best, A. Dechêne, G. Gerken, J. F Schlaak, A. Weinmann, M. A. Wörns, P. Galle, W. Yeo, F. Mo, S. L. Chan, H. Reeves, T. Cox, P. Johnson. Diagnosis and prognostication in hepatocellular carcinoma: Application of the GALAD and BALAD-2 serology models (2016). J. Clin. Pathol, 69(7):619-26.
     
     
135. Bertram, J. Padden, J. Kaelsch, M. Ahrens, L. Pott, A. Canbay, F. Weber, C. Fingas, A. C Hoffmann, A. Vietor, J. F Schlaak, M. Eisenacher, H. Reis, B. Sitek, H. A Baba. Novel immunohistochemical markers differentiate intrahepatic cholangiocarcinoma from benign bile duct lesions (2016). J. Clin. Pathol., 14(6):875-886
     
     
136. I. Real, M. Lu, J. Liu, X. Huang, M. Trippler, M. Hossbach, J. Deckert, K. Jahn-Hofmann, L. M. Ickenstein, M. J. John, K. Gibbert, U. Dittmer, H.-P. Vornlocher, R. Schirmbeck, G. Gerken, J. F. Schlaak, R. Broering. Hepatitis B virus genome replication triggers toll-like receptor 3-dependent interferon responses in the absence of hepatitis B surface antigen (2016). Sci. Rep., 28;6:24865.
     
     
137. Levy, N. Habib, M.A. Guzzardi, D. Kitsberg, D. Bomze, E. Ezra, B.E. Uygun, K. Uygun, M. Trippler, J.F. Schlaak, O. Shibolet, E.H. Sklan, M. Cohen, J. Timm, N. Friedman, Y. Nahmias. Nuclear receptors control pro-viral and antiviral metabolic responses to hepatitis C virus infection (2016). Nat. Chem. Biol., 12(12):1037-1045.
     
     
138. A. Megger, K. Rosowski, M. Ahrens, T. Bracht, M. Eisenacher, J. F. Schlaak, F. Weber, A.-C. Hoffmann, H. E. Meyer, H. A. Baba, B. Sitek. Tissue-based quantitative proteome analysis of human hepatocellular carcinoma using tandem mass tags (2016). Biomarkers, 28:1-10.
     
     
139. A. Megger, J. Padden, K. Rosowski, J. Uszkoreit, T. Bracht, M. Eisenacher, C. Gerges, H. Neuhaus, B. Schumacher, J. F. Schlaak, B. Sitek. One Sample, One Shot - Evaluation of sample preparation protocols for the mass spectrometric proteome analysis of human bile fluid without extensive fractionation (2017). J. Proteomics, 154:13-21.
     
     
140. I. Real, M. Werner, A. Paul, G. Gerken, J. F. Schlaak, A. Vaillant, R. Broering. Nucleic acid-based polymers effective against hepatitis B Virus infection in patients don´t harbor immunostimulatory properties in primary isolated liver cells (2017). Sci. Rep., Mar 8;7:43838.
     
     
141. Katsounas, K. R. Wilting, R. A. Lempicki, J. F. Schlaak, G. Gerken. Microarrays-Enabled Hypothesis Generation: The Suspect Role of FNBP-1 in Neuropsychiatric Pathogenesis Associated with HIV and/or HCV Infection (2016). J AIDS Clin Res. 7(12). pii: 641
     
     
142. Zhang Z., Trippler M., Real C., Werner M., Kemper T., Treckmann J., Paul A., Baba H., Gerken G., Wedemeyer H., Schlaak J. F., Lu M., Broering R. Hepatitis B virus activates toll-like receptor 2-dependent immune signaling while entering primary human hepatocytes (2020), Hepatology, Sep;72(3):829-844. doi: 10.1002/hep.31112. Epub 2020 Jul 11.
     
     
143. Werner, S. Schefczyk, M. Trippler, J.W. Treckmann, H.A. Baba, G. Gerken, J.F. Schlaak, R. Broering. Antiviral Toll-like Receptor Signaling in Non-Parenchymal Liver Cells Is Restricted to TLR3 (2022). Viruses. 2022 Jan 24;14(2):218. doi: 10.3390/v14020218.

1. Wölfel, P. Schirmacher, J. F. Schlaak, P. Knolle, H.-P. Dienes, W. Dippold, K.-H. Meyer zum Büschenfelde, G. Gerken. Sustained elimination of hepatitis B virus from serum induced in a patient with chronic hepatitis B and advanced human immunodeficiency virus infection (1994). Clin. Investig. 72, 1030-1036.
   
   
2. Schramm, J.F. Schlaak, P.R. Galle. Rapid development of Epstein-Barr virus-associated Hodgkin's disease after cessation of foscarnet therapy in an HIV-infected patient (2000). Int.J.STD AIDS 11[9], 609-610.
   
   
3. C. Sotiropoulos, J. Treckmann, A. Radtke, G. Antoch, E. Brokalaki, J.F. Schlaak, C. E. Broelsch. Arterioportal fistula complicating endoscopic retrograde cholangiography (2005). Endoscopy 37[1], 93-4.
   
   
4. Katsounas, C. Jochum, A. Canbay, J.F. Schlaak, W. Gerlich, G. Gerken. Core Promoter Mutant HBV Non-responding To Adefovir after Viral Breakthrough on Lamivudine: Rapid Virologic Response to Tenofovir Plus Lamivudine in a Cirrhotic Patient (2008). Eur J Med Res. 27;13(10):472-5.
   
   
5. Abendroth, R. Klein, J.F. Schlaak, K.A. Metz, G.J. Dobos, J. Langhorst. Imposanter Befund einer Melanosis coli nach jahrzehntelangem Abusus von Anthrachinonderivaten - Ein Risikofaktor für kolorektale Neoplasien (2009)? Z. Gastroent. 47 (6), 579-82.
   
   
6. Buechter, C. G. Klein, C. Kloeters, J.F. Schlaak, A. Canbay, G. Gerken, A. Kahraman. Tacrolimus as a reasonable alternative in a patient with steroid-dependent and thiopurine-refractory autoimmune pancreatitis with IgG4-associated cholangitis (2014). Z Gastroenterol. 52(6):564-568.

1. Knolle, H. Löhr, U. Treichel, H.-P. Dienes, A. Lohse, J. F. Schlaak, G.Gerken (1995): Parenchymal and nonparenchymal liver cells and their interaction in the local immune response. Z. f. Gastroenterol., 33, 613-620.
   
   
2. F. Schlaak, H. Koehler, G.Gerken (1996): Hepatitis G virus: an old, but newly discovered hepatotropic virus. Is it of interest for the nephrologist ?. Nephrol.Dial.Transplant. 11[8], 1522-1523.
   
   
3. F. Schlaak, G. Gerken (1997): Aktuelle Strategie in der Diagnostik und Therapie der chronischen Virushepatitiden. Tägl. prax., 38, 515-526.
   
   
4. F. Schlaak, G. Gerken (1997): Diagnose und Therapie der chronischen Virushepatitiden. Internist. prax., 37, 519-530.
   
   
5. F. Schlaak (1997): Virushepatitiden – Verlauf und extrahepatische Manifestationen. Krankenhaus Arzt, 70, 8-9.
   
   
6. F. Schlaak, G. Gerken (1997): Chronische Hepatitiden. Differentialdiagnostik und Therapie. Fortschr. Med.115:34-36.
   
   
7. F. Schlaak, G. Gerken (1997): G. Chronische Hepatitiden. Differentialdiagnose der Hepatitis C. Fortschr. Med.115:38-39.
   
   
8. F. Schlaak, G. Gerken (1997): Chronische Hepatitiden. Differentialdiagnose der Hepatitis B, D und G. Fortschr. Med.115:44-46.
   
   
9. F. Schlaak, G. Gerken (1997): Chronische Hepatitiden. Diagnose der autoimmunen Lebererkrankungen. Fortschr. Med. 115:33-34.
   
   
10. F. Schlaak, G. Gerken (1997): Chronische Hepatitiden: Therapie der chronischen Virushepatitiden. Fortschr. Med. 115:48-50.
    
    
11. F. Schlaak, G. Gerken (1997): Chronische Hepatitiden: Therapie der autoimmunen Leberkrankungen. Fortschr. Med. 115:52-53.
    
    
12. Wu, R. Bröring, J. F. Schlaak. The role of the innate immune system of the liver in the control of HBV and HCV (2008). Virologica Sinica 23 (2): 116-123.
    
    
13. Ertle, T. Lauenstein, J. F. Schlaak. Benefit of using TARE-Y90 comparing with TACE in the management of primary and secondary liver tumors (2011). Eur. J. Clin. Med. Oncol., 3(1): 44-50.
    
    
14. Katsounas, J. F. Schlaak, R. A. Lempicki. CCL5: A Double-edged Sword in Host Defense against the Hepatitis C Virus (2011). Int. Rev. Immunol., 30(5-6):366-78. IF: 2,641
    
    
15. Broering, M. Lu, J. F. Schlaak. Role of Toll-like receptors in liver health and disease (2011). Clin. Science, 1;121(10):415-26. IF: 4,613
    
    
16. Zhang, A. Kraft, R. Broering, J. F. Schlaak, U. Dittmer, M. Lu. Preclinical development of TLR ligands as drugs for the treatment of chronic viral infections (2012). Exp. Opin. Curr. Drug Disc., 7(7):597-611.
    
    
17. Ertle, G. Gerken, J. F. Schlaak. Lokalablative Therapien zur Behandlung des hepatozellulären Karzinoms (2012). Der Gastroenterologe, in press.
    
    
18. Ertle, G. Gerken, J. F. Schlaak. Radioembolisation bei forgeschrittenem hepatozellulären Karzinom. Viszeralmedizin (2012). Viszeralmed. 28(5), 311-16.
    
    
19. Gibbert, J. F. Schlaak, D. L. Yang, U. Dittmer. Interferon alpha subtypes: Distinct Biological activities in anti-viral therapy (2012). Br. J. Pharm., 168(5):1048-58.
    
    
20. Lang, J. Ricke, J.F. Schlaak. Resektion oder interventionelle Therapie beim hepatozellulären Karzinom: welche Methode für welchen Patienten (2013)? Dtsch Med Wochenschr. 138(36):1780-4.
    
    
21. F. Schlaak. Zufallsbefund Leberrundherd: Bösartig oder gutartig (2013)? Der Allgemeinarzt, 11:34-38.
    
    
22. F. Schlaak. Labordiagnostik bei primärem Leberzellkarzinom (2014). Der Gastroenterologe, 9:138-144.
    
    
23. Nel, P. David, G. Gerken, J. F. Schlaak, A.-C. Hoffmann. Role of circulating tumor cells and cancer stem cells in hepatocellular carcinoma (2014). Hepatol. Int., 8(3):321-9.
    
    
24. Hoyo-Becerra, J. F. Schlaak, D. M. Hermann. Insights from interferon-alpha-related depression for idiopathic major depression (2014). Brain Behav. Immun., 42:222-31.
    
    
25. F. Schlaak. Radioembolisation with yttrium-90 glass microspheres for patients with hepatocellular carcinoma: a review (2014). Hep. Oncol., 1(4): 387-393.
    
    
26. Wu, M. Han, J. Li, X. Yang, X. Zhen, J.F. Schlaak, D. Yang, M. Lu. Pattern Recognition Receptors and Liver Failure (2019). Crit Rev Immunol. 2019;39(4):289-311. doi:10.1615/CritRevImmunol.2019031012.
    
    
27. [When should methotrexate hepatopathy be suspected and which measures are advisable?]. D. Passens, F. Schlaak.Z Rheumatol. 2022 Feb;81(1):67-70. doi: 10.1007/s00393-021-01136-7. Epub 2021 Dec 3.

1. F. Schlaak, G. Gerken (1997): HCV-Koinfektionen. In: Hepatitis C, Häussinger, Niederau (Hrsg.), Blackwell Wissenschafts-Verlag, Berlin, Wien.
   
   
2. F. Schlaak, G. Gerken (2001): HCV-Koinfektionen. In: Hepatitis C, Häussinger, Niederau (Hrsg.), Blackwell Wissenschafts-Verlag, Berlin, Wien.
   
   
3. F. Schlaak, G. Gerken (2003): Das primäre Leberzellkarzinom als Folge der Hepatitis B- und C-Infektion. In: Virushepatitis als Berufskrankheit, Selmair, Manns (Hrsg.), Ecomed Verlag, Landsberg.
   
   
4. F. Schlaak, G. Gerken (2004): Management of IL-2 toxicity. In: Immunotreatment and gene therapy of HIV infection, Hengge, Kabelitz (Hrsg.), Unimed Verlag, Bremen.
   
   
5. Canbay, J. F. Schlaak, G. Gerken, R. Gieseler (2007). Dysregulated Apoptosis in Liver Diseases. In : Cell apoptosis: Regulation and environmental factors, (Schultz (Hrsg.), Nova Science Publishers, Inc, New York, USA.
   
   
6. F. Schlaak, G. Gerken (2007): Das primäre Leberzellkarzinom als Folge der Hepatitis B- und C-Infektion. In: Virushepatitis als Berufskrankheit, Selmair, Manns (Hrsg.), Ecomed Verlag, Landsberg.
   
   
7. Jochum, J.F. Schlaak (2010). Hepatitis C: Symptoms, Diagnosis and Treatment, pp. 135-158 In: Advances in Medicine and Biology, Vol. 9, (Bernhardt (Hrsg.), Nova Science Publishers, Inc, New York, USA.
   
   
8. Bröring, M. Lu, J.F. Schlaak (2011). Toll like receptors in chronic viral hepatitis – friend and foe. In: Viral Hepatitis, ISBN 979-953-307-103-8, InTech, Rijeka, Croatia.

Universität Mainz:

• SS90-WS90/91: Kursus in Anamnese und allgemeiner klinischer Untersuchung
• SS92-WS92/93: Kursus in Anamnese und allgemeiner klinischer Untersuchung
• SS96: Vorlesung „Allgemeinmedizin und Klinik“
• WS97/98-WS99/00: Vorlesung Anamnese und allgemeine klinische Untersuchung
• SS95-WS99/00: Praktikum Innere Medizin I und II
• SS97-WS99/00: Praktikum Innere Medizin III

Universitätsklinikum Essen:

• WS01/02-6/2013 Vorlesung Pathophysiologie
• Vorlesung Innere Medizin
• Vorlesung Infektionsimmunologie
• Bedsideteaching Innere Medizin
• PJ-Fortbildung Pankreaserkrankungen Innere Medizin
• PJ-Fortbildung Lebererkrankungen Innere Medizin

Chefarzttätigkeit seit 2013:

• 7/2013-dato Blockpraktikum Innere Medizin (UK Essen)
• Vorlesung Medizinische Biologie (UK Essen)
• Vorlesung Innere Medizin (UK Essen)
• Blockpraktikum Innere Medizin (UK Düsseldorf)
• PJ-Fortbildung Innere Medizin